Stem cell research has often been considered controversial. But over the last few decades great strides have been made, with the science community better understanding — and the general population more fully aware of — how adult stem cells (not just those residing in embryos) work. Indeed, with modern medicine moving beyond embryonic stem cell research and the frequent ethical conversations surrounding the use of them for medical treatments, fledgling biotech companies are finally in a position to actively pursue public funds; after all, it’s a lot easier to convince the public to support your work if you can prove it’s NOT as controversial an investment as previously believed. Take a look at four reasons stem cell stocks might be a good risk to take in 2021:
Worldwide Population is Aging
In 2018, for the first time in recorded history, there were more people over 65 than under five years of age. Furthermore, world population data projections estimate that “by 2050, one out of six people will be over the age of 65 years, and the number of people age 80 and above will have tripled. People are living longer, having fewer babies and traveling farther afield, causing shifts to global age structures throughout the world. Chronic disease is on the horizon, conditions that result from living longer and for which there will be an increased demand to treat. Since stem cells are the foundation of treatments aimed at ameliorating the effects of disease, injury and degeneration (often resulting from age-related issues) investing in their discovery and production could likely result in lucrative profits.
Modern Medicine is Moving Toward Regenerative Technologies for Routine Care
Now, more than ever, modern medicine is moving away from traditional therapeutic care, preferring instead to actually reverse damage rather than just treat symptoms of disease. What was once considered “sci-fi” is now becoming standard medical practice. Because of this shift, it is highly unlikely that stem cells won’t remain at the forefront of scientific interest since they play such an enormous role in development of curative care treatments.
FDA is Granting Increased Number of RMATs
Perhaps in response to increased public and scientific interest in regenerative medicine techniques, the U.S. Food and Drug Administration (FDA) is granting Regenerative Medicine Advanced Therapy (RMAT) designations to more and more cell and gene therapy protocols. This means companies can proceed to clinical trials and possible public offerings with the fruits of their research; with federal regulations granting greater access to stem cell treatments, the time has never been better for investors to play a role in getting potential drugs and protocols on the market.
Stem Cells Improve Lives
Finally, investing in stem cell stocks is investing in human lives. Research proves the potential for stem cells to regenerate tissue. Clinics like ThriveMD, for instance, are using adult stem cells to treat common, yet still debilitating conditions. They are easing patients’ pain, making it easier for them to live healthier and happier lives. Who wouldn’t believe that to be a good enough reason to financially support stem cell research?!